Drug duo targets Hard-to-Treat IDH-Mutated tumors

NCT ID NCT03991832

Ongoing Disease control Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether combining two drugs—olaparib and durvalumab—can shrink or control solid tumors that have an IDH mutation. The study includes adults with certain brain tumors (glioma) or bile duct cancer (cholangiocarcinoma) that have not responded well to prior therapy. Olaparib blocks a protein that helps cancer cells grow, while durvalumab helps the immune system attack cancer cells. The goal is to see if the pair works better than either drug alone.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: olaparib and durvalumab
What this could lead to: If successful, this drug combination could offer a new treatment option for people with IDH-mutated cancers, potentially slowing tumor growth or shrinking tumors.
What could go wrong: This is an early-phase trial with a small number of participants, so results may not apply to everyone. The combination may cause side effects or fail to work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHOLANGIOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cholangiocarcinoma glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHOLANGIOCARCINOMA GLIOMA IDH MUTATION SOLID TUMOR

Contacts and locations

Locations

Princess Margaret Cancer Centre

Toronto, Ontario, M5G 2M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.